Header Logo

Connection

Nicola Klein to Aged, 80 and over

This is a "connection" page, showing publications Nicola Klein has written about Aged, 80 and over.
Connection Strength

0.625
  1. Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention. Vaccine. 2019 08 23; 37(36):5422-5427.
    View in: PubMed
    Score: 0.113
  2. Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine. 2016 08 05; 34(36):4293-7.
    View in: PubMed
    Score: 0.092
  3. Lack of association of Guillain-Barré syndrome with vaccinations. Clin Infect Dis. 2013 Jul; 57(2):197-204.
    View in: PubMed
    Score: 0.073
  4. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet. 2024 Oct 19; 404(10462):1547-1559.
    View in: PubMed
    Score: 0.041
  5. Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study. JMIR Public Health Surveill. 2024 Jun 25; 10:e53807.
    View in: PubMed
    Score: 0.040
  6. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
    View in: PubMed
    Score: 0.034
  7. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
    View in: PubMed
    Score: 0.033
  8. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.033
  9. Evaluation of two frailty indices, with practical application in a vaccine clinical trial. Hum Vaccin Immunother. 2019; 15(12):2960-2968.
    View in: PubMed
    Score: 0.028
  10. Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink Project. Vaccine. 2019 05 31; 37(25):3296-3302.
    View in: PubMed
    Score: 0.028
  11. Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. BMC Pulm Med. 2017 Dec 16; 17(1):208.
    View in: PubMed
    Score: 0.025
  12. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine. J Infect Dis. 2017 12 12; 216(11):1343-1351.
    View in: PubMed
    Score: 0.025
  13. Risk of venous thromboembolism following influenza vaccination in adults aged 50years and older in the Vaccine Safety Datalink. Vaccine. 2017 10 13; 35(43):5872-5877.
    View in: PubMed
    Score: 0.025
  14. Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2012 Nov 26; 30(50):7253-9.
    View in: PubMed
    Score: 0.018
  15. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. Vaccine. 2011 Oct 26; 29(46):8302-8.
    View in: PubMed
    Score: 0.016

© 2024 Kaiser Permanente